ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Kjell Oberg, Anne Couvelard, Gianfranco Delle Fave, David Gross, Ashley Grossman, Robert T. Jensen, Ulrich Frank Pape, Aurel Perren, Guido Rindi, Philippe Ruszniewski, Jean Yves Scoazec, Staffan Welin, Bertram Wiedenmann, Diego Ferone

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: Serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called "general tumor markers." The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

Original languageEnglish
Pages (from-to)201-211
Number of pages11
JournalNeuroendocrinology
Volume105
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Neuroendocrine Tumors
Standard of Care
Tumor Biomarkers
Biomarkers
Guidelines
Hydroxyindoleacetic Acid
Chromogranin A
Phosphopyruvate Hydratase
Serotonin
Circulating Neoplastic Cells
Sensitivity and Specificity
Neoplasms
Gastrins
Gastrointestinal Tract
Randomized Controlled Trials
High Pressure Liquid Chromatography
Hormones
Insulin
Lung
Messenger RNA

Keywords

  • Biomarkers
  • Chromogranin A
  • Neuroendocrine tumor test
  • Urinary 5-hydroxyindoleacetic acid

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cellular and Molecular Neuroscience

Cite this

Oberg, K., Couvelard, A., Delle Fave, G., Gross, D., Grossman, A., Jensen, R. T., ... Ferone, D. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 105(3), 201-211. https://doi.org/10.1159/000472254

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : Biochemical Markers. / Oberg, Kjell; Couvelard, Anne; Delle Fave, Gianfranco; Gross, David; Grossman, Ashley; Jensen, Robert T.; Pape, Ulrich Frank; Perren, Aurel; Rindi, Guido; Ruszniewski, Philippe; Scoazec, Jean Yves; Welin, Staffan; Wiedenmann, Bertram; Ferone, Diego.

In: Neuroendocrinology, Vol. 105, No. 3, 01.09.2017, p. 201-211.

Research output: Contribution to journalArticle

Oberg, K, Couvelard, A, Delle Fave, G, Gross, D, Grossman, A, Jensen, RT, Pape, UF, Perren, A, Rindi, G, Ruszniewski, P, Scoazec, JY, Welin, S, Wiedenmann, B & Ferone, D 2017, 'ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers', Neuroendocrinology, vol. 105, no. 3, pp. 201-211. https://doi.org/10.1159/000472254
Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology. 2017 Sep 1;105(3):201-211. https://doi.org/10.1159/000472254
Oberg, Kjell ; Couvelard, Anne ; Delle Fave, Gianfranco ; Gross, David ; Grossman, Ashley ; Jensen, Robert T. ; Pape, Ulrich Frank ; Perren, Aurel ; Rindi, Guido ; Ruszniewski, Philippe ; Scoazec, Jean Yves ; Welin, Staffan ; Wiedenmann, Bertram ; Ferone, Diego. / ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : Biochemical Markers. In: Neuroendocrinology. 2017 ; Vol. 105, No. 3. pp. 201-211.
@article{ba5530fdb13f485e812c2096b0c56427,
title = "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers",
abstract = "Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: Serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called {"}general tumor markers.{"} The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90{\%}. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.",
keywords = "Biomarkers, Chromogranin A, Neuroendocrine tumor test, Urinary 5-hydroxyindoleacetic acid",
author = "Kjell Oberg and Anne Couvelard and {Delle Fave}, Gianfranco and David Gross and Ashley Grossman and Jensen, {Robert T.} and Pape, {Ulrich Frank} and Aurel Perren and Guido Rindi and Philippe Ruszniewski and Scoazec, {Jean Yves} and Staffan Welin and Bertram Wiedenmann and Diego Ferone",
year = "2017",
month = "9",
day = "1",
doi = "10.1159/000472254",
language = "English",
volume = "105",
pages = "201--211",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors

T2 - Biochemical Markers

AU - Oberg, Kjell

AU - Couvelard, Anne

AU - Delle Fave, Gianfranco

AU - Gross, David

AU - Grossman, Ashley

AU - Jensen, Robert T.

AU - Pape, Ulrich Frank

AU - Perren, Aurel

AU - Rindi, Guido

AU - Ruszniewski, Philippe

AU - Scoazec, Jean Yves

AU - Welin, Staffan

AU - Wiedenmann, Bertram

AU - Ferone, Diego

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: Serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called "general tumor markers." The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

AB - Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: Serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called "general tumor markers." The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

KW - Biomarkers

KW - Chromogranin A

KW - Neuroendocrine tumor test

KW - Urinary 5-hydroxyindoleacetic acid

UR - http://www.scopus.com/inward/record.url?scp=85018492019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018492019&partnerID=8YFLogxK

U2 - 10.1159/000472254

DO - 10.1159/000472254

M3 - Article

AN - SCOPUS:85018492019

VL - 105

SP - 201

EP - 211

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 3

ER -